{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=66", "query": { "condition": "Solid Tumor Malignancies, Cancer", "page": 66 }, "page_size": 10 }, "pagination": { "page": 66, "page_size": 10, "total_count": 5458, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=67&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=65&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T20:04:17.964Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02717156", "title": "Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Bladder Urothelial Carcinoma", "Prostate Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2016-11-21", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717156" }, { "nct_id": "NCT01023737", "title": "Hydroxychloroquine + Vorinostat in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumour" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 72, "start_date": "2009-11", "completion_date": "2023-01-08", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023737" }, { "nct_id": "NCT03157128", "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Medullary Thyroid Cancer", "Colon Cancer", "Any Solid Tumor" ], "interventions": [ { "name": "LOXO-292", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 857, "start_date": "2017-05-02", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 41, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03157128" }, { "nct_id": "NCT07159828", "title": "A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "AXN-2510", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Axion Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-09-15", "completion_date": "2026-04-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 7, "location_summary": "Huntersville, North Carolina • Dallas, Texas • Houston, Texas + 2 more", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159828" }, { "nct_id": "NCT04317105", "title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-07-17", "completion_date": "2027-05-06", "has_results": true, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Austin, Texas • Galveston, Texas + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" }, { "city": "Galveston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317105" }, { "nct_id": "NCT03681951", "title": "First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Pancreatic" ], "interventions": [ { "name": "GSK3145095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-11-16", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03681951" }, { "nct_id": "NCT03784677", "title": "A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Ovarian Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "TRPV6 Calcium Channel Inhibitor SOR-C13", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-07-29", "completion_date": "2023-06-20", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784677" }, { "nct_id": "NCT02222922", "title": "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-06647020 Q3W", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" }, { "name": "PF-06647020 Q2W", "type": "DRUG" }, { "name": "PF-06647020 combined with Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2014-10-17", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222922" }, { "nct_id": "NCT02157831", "title": "Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "CP-870,893", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-07", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02157831" }, { "nct_id": "NCT04374877", "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "CHS-388", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2020-04-22", "completion_date": "2025-06-05", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-28T20:04:17.964Z", "location_count": 18, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04374877" } ] }